Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDNO Infusion in Post-Operative Pulmonary Hypertension
NCT05699486Phase 2Unknown
- Sponsor
- Attgeno AB
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PDNO in pulmonary hypertension (PH), sponsored by Attgeno AB. Primary endpoint: Mean change in Pulmonary Vascular Resistance. Status: unknown.
02
Drugs
PDNO
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT05699486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05699486.